Upstream Bio, Inc. (UPB): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$133.28M

Year ended 2025-12-31

-$136.34M

Trailing 12 months to 2026-06-30

2023-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$133.28M	n/m	2026-03-26, From 2025-01-01
2024-12-31	-$59.17M	n/m	2026-03-26, From 2024-01-01
2023-12-31	-$37.93M	n/a	2025-03-12, From 2023-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Upstream Bio, Inc. (UPB)	2025-12-31	-$133.28M	n/m
Cartesian Therapeutics, Inc. (RNAC)	2025-12-31	-$73.94M	n/m
Xenetic Biosciences, Inc. (XBIO)	2025-12-31	-$2.29M	n/m
TherapeuticsMD, Inc. (TXMD)	2025-12-31	$2.45M	+109.7%
GeoVax Labs, Inc. (GOVX)	2025-12-31	-$21.47M	n/m
Camp4 Therapeutics Corp (CAMP)	2025-12-31	-$29.55M	n/m
Marker Therapeutics, Inc. (MRKR)	2025-12-31	-$12.01M	n/m
Korsana Biosciences, Inc. (KRSA)	2025-12-31	-$3.31M	n/m
Dianthus Therapeutics, Inc. (DNTH)	2025-12-31	-$129.06M	n/m

Compare UPB, RNAC, XBIO, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗